Oculis Holding AG (OCS) Research & Development (2022 - 2026)
Oculis Holding AG (OCS) recorded quarterly Research & Development of -$17.9 million in Q1 2026, down 7.89% quarter-over-quarter from -$16.6 million in Q4 2025, and down 9.18% on a YoY basis from -$19.7 million in Q1 2025.
Oculis Holding AG (OCS) Research & Development (2022 - 2026) Analysis & Trends
Oculis Holding AG's Research & Development history runs 5 years deep, the most recent figure standing at -$17.9 million for Q1 2026.
- In Q1 2026, Research & Development fell 9.18% year-over-year to -$17.9 million; the TTM figure through Mar 2026 stood at -$17.7 billion (down 17.6% YoY), while the FY2025 annual figure was -$71.4 million, down 20.13% from the prior year.
- Research & Development was -$17.9 million for Q1 2026 at Oculis Holding AG, down from -$16.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of -$4.8 million in Q3 2022 to a low of -$17.6 billion in Q3 2025.
- Historically, Research & Development has averaged -$2.1 billion across 5 years, with a median of -$12.9 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Research & Development plunged 149271.33% in 2024, then increased 1.09% in 2025.
- A 5-year view of Research & Development shows it stood at -$7.2 million in 2022, then decreased by 26.58% to -$9.1 million in 2023, then sank by 48.35% to -$13.4 million in 2024, then fell by 23.82% to -$16.6 million in 2025, then dropped by 7.89% to -$17.9 million in 2026.
- The last three Research & Development figures came in at -$17.9 million (Q1 2026), -$16.6 million (Q4 2025), and -$17.6 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -58.00 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | -17.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.94 Mn |
| Dec 31, 2025 | -16.63 Mn |
| Sep 30, 2025 | -17.65 Bn |
| Jun 30, 2025 | -18.01 Mn |
| Mar 31, 2025 | -16.43 Mn |
| Dec 31, 2024 | -13.43 Mn |
| Sep 30, 2024 | -15.00 Bn |
| Jun 30, 2024 | -18.21 Mn |
| Mar 31, 2024 | -12.44 Mn |
| Dec 31, 2023 | -9.05 Mn |
| Sep 30, 2023 | -10.04 Mn |
| Jun 30, 2023 | -6.89 Mn |
| Mar 31, 2023 | -6.65 Mn |
| Dec 31, 2022 | -7.15 Mn |
| Sep 30, 2022 | -4.75 Mn |
| Jun 30, 2022 | -6.96 Mn |